Please login to the form below

Not currently logged in
Email:
Password:

Merck & Co appoints new financial head

Baxter’s Robert Davis takes over from Peter Kellogg
Robert Davis Merck

Merck & Co's long-time chief financial officer Peter Kellogg is to step down within the next two months and will be replaced by Baxter's Robert Davis.

Kellogg had been in the position since joining Merck in 2007 and played a key role in the pharma company's merger with Schering-Plough.

To help with the transition, Kellogg will work closely with Davis (pictured) when he joins on April 23, staying with Merck until May 16.

Davis, who currently serves as VP and president of Baxter's medical products business – a role he has held since 2010, also has great industry experience.

He first joined Baxter in 2004 as chief financial officer of the company's renal business and prior to this spent 14 years at Lilly.

Commenting on the departure of Kellogg, Merck's CEO Kenneth Frazier said: "Peter has been an important member of the Merck leadership team and instrumental in helping to guide Merck during a period of significant change at our company and in our industry.”

31st March 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...